World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
51
Citations
13740
World Ranking
16975
National Ranking
6999

Overview

Yael P. Mosse is affiliated with the Children's Hospital of Philadelphia in the United States. Their research primarily spans the fields of medicine, biochemistry, genetics, and molecular biology, with a focused subfield concentration in neurology, molecular biology, cancer research, oncology, and genetics.

Their main topics of work include neuroblastoma research and treatments, cancer, hypoxia, and metabolism, cancer therapeutics and mechanisms, lung cancer research studies, virus-based gene therapy research, ubiquitin and proteasome pathways, as well as lung cancer treatments and mutations.

Frequent co-authors collaborating with Yael P. Mosse are:

  • John M. Maris
  • Kateryna Krytska
  • Julie R. Park
  • Malcolm A. Smith
  • David Groff

Key venues where Yael P. Mosse's research has been published include:

  • Cancer Research
  • Journal of Clinical Oncology
  • Pediatric Blood & Cancer
  • Clinical Cancer Research
  • Cancer Discovery

Several notable recent papers authored or co-authored by Yael P. Mosse are:

  • The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models (2021), published in Clinical Cancer Research
  • Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912) (2021), published in Clinical Cancer Research
  • Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results (2023), published in Nature Medicine
  • Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium (2021), published in Journal of Clinical Oncology
  • Drugging the "Undruggable" MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers (2021), published in Cancer Research

Best Publications

  • Identification of ALK as a major familial neuroblastoma predisposition gene

    Yaël P. Mossé;Marci Laudenslager;Luca Longo;Kristina A. Cole

  • The genetic landscape of high-risk neuroblastoma

    Trevor J Pugh;Olena Morozova;Edward F Attiyeh;Edward F Attiyeh;Shahab Asgharzadeh;Shahab Asgharzadeh

  • Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study

    Yael P Mossé;Megan S Lim;Stephan D Voss;Keith Wilner

  • Chromosome 1p and 11q deletions and outcome in neuroblastoma.

    Edward F. Attiyeh;Wendy B. London;Yael P. Mossé;Qun Wang

  • The Human Tumor Atlas Network: Charting Tumor Transitions Across Space and Time at Single-Cell Resolution

    Orit Rozenblatt-Rosen;Aviv Regev;Aviv Regev;Aviv Regev;Philipp Oberdoerffer;Tal Nawy

  • Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.

    Yael P. Mossé;Stephan D. Voss;Megan S. Lim;Delphine Rolland

  • ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma

    Scott C. Bresler;Daniel A. Weiser;Daniel A. Weiser;Peter J. Huwe;Jin H. Park

  • A Functional Screen Identifies miR-34a as a Candidate Neuroblastoma Tumor Suppressor Gene

    Kristina A. Cole;Edward F. Attiyeh;Yael P. Mosse;Michael J. Laquaglia

  • Common variations in BARD1 influence susceptibility to high-risk neuroblastoma

    Mario Capasso;Marcella Devoto;Cuiping Hou;Shahab Asgharzadeh

  • Integrative genomics identifies LMO1 as a neuroblastoma oncogene

    Kai Wang;Kai Wang;Sharon J. Diskin;Haitao Zhang;Edward F. Attiyeh

  • Chromosome 6p22 Locus Associated with Clinically Aggressive Neuroblastoma

    John M. Maris;Yael P. Mosse;Jonathan P. Bradfield;Cuiping Hou

  • RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma

    Kristina A. Cole;Jonathan Huggins;Michael Laquaglia;Chase E. Hulderman

  • Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma

    Scott C. Bresler;Andrew C. Wood;Andrew C. Wood;Elizabeth A. Haglund;Elizabeth A. Haglund;Joshua Courtright;Joshua Courtright

  • Inhibition of ALK signaling for cancer therapy.

    Yael P. Mossé;Andrew Wood;John M. Maris

  • Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number.

    Qun Wang;Sharon Diskin;Eric Rappaport;Edward Attiyeh

  • STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments

    Sharon J. Diskin;Thomas Eck;Joel Greshock;Yael P. Mosse

  • Phenotype Restricted Genome-Wide Association Study Using a Gene-Centric Approach Identifies Three Low-Risk Neuroblastoma Susceptibility Loci

    Lễ B. Nguyễn;Lễ B. Nguyễn;Sharon J. Diskin;Mario Capasso;Kai Wang

  • Retinoblastoma and Neuroblastoma Predisposition and Surveillance.

    Junne Kamihara;Franck Bourdeaut;William D. Foulkes;Jan J. Molenaar

  • Targeting ALK in neuroblastoma—preclinical and clinical advancements

    Erica L. Carpenter;Yael P. Mossé

  • Prevalence and functional consequence of PHOX2B mutations in neuroblastoma

    E H Raabe;M Laudenslager;C Winter;N Wasserman

Frequent Co-Authors

John M. Maris
John M. Maris Children's Hospital of Philadelphia
Hakon Hakonarson
Hakon Hakonarson Children's Hospital of Philadelphia
Malcolm A. Smith
Malcolm A. Smith National Institutes of Health
Wendy B. London
Wendy B. London Harvard University
Katherine K. Matthay
Katherine K. Matthay University of California, San Francisco
Robert C. Seeger
Robert C. Seeger Children's Hospital of Los Angeles
Mark A. Lemmon
Mark A. Lemmon Yale University
Michael D. Hogarty
Michael D. Hogarty Children's Hospital of Philadelphia
Marcella Devoto
Marcella Devoto University of Pennsylvania
Peter C. Adamson
Peter C. Adamson Children's Hospital of Philadelphia

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're studying Biology or Biochemistry, there are several emerging online degrees and career opportunities worth considering. The demand for professionals in medical coding and billing is on the rise, offering strong job security. Those curious about what is medical coding salary can expect a competitive income, especially with experience and certifications.

Wondering is medical coding a good career? Many find it appealing due to its remote work options, flexibility, and key role in healthcare data management. For those looking to advance in health information systems, there are reputable health information management schools online that provide affordable pathways to this in-demand career.

Additionally, nutrition is a popular field among Biology graduates. If you are interested in deepening your expertise in wellness and dietetics, consider pursuing an online masters degree in nutrition for greater career flexibility and advancement.

Best Scientists Citing Yael P. Mosse

Trending Scientists

Recently Published Articles